| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Cetyl glycol does not have a well-defined pharmacological target. It is used as an emollient and moisturizer in cosmetic formulations. It may have skin-conditioning properties. It is not intended for systemic pharmacological effects. It is a long-chain diol that acts as a humectant and emollient by forming a barrier on the skin surface.
|
|---|---|
| ln Vitro |
In vitro, cetyl glycol is used as an emollient and moisturizer in cosmetic formulations. It has skin-conditioning properties. Its in vitro activities are related to its physicochemical properties rather than specific pharmacological effects. It is used as a chemical intermediate and cosmetic ingredient.
|
| ln Vivo |
In vivo, cetyl glycol is used as an emollient and moisturizer in cosmetic and personal care products. It is applied topically to the skin to provide hydration and improve skin texture. It is also used as a thickening agent and emulsifier in various formulations. Its in vivo effects are limited to its topical applications.
|
| Enzyme Assay |
General protocols for skin hydration studies use human volunteers or reconstructed skin models. Cetyl glycol is formulated into a cream or lotion at concentrations of 1-10%. The formulation is applied to the skin, and hydration is measured using a corneometer at baseline and at various time points post-application. Skin barrier function is assessed by measuring transepidermal water loss (TEWL). The compound's moisturizing efficacy is compared to placebo or reference formulations.
|
| Cell Assay |
General protocols for cell-based studies using cetyl glycol are limited. The compound is primarily used as a cosmetic ingredient. For cytotoxicity studies, keratinocytes or fibroblasts are seeded in 96-well plates and treated with cetyl glycol at various concentrations (1-1000 µM) for 24-72 hours. Cell viability is assessed by MTT or CCK-8 assays. The compound's safety for topical use is evaluated.
|
| Animal Protocol |
Cetyl glycol is a long-chain diol used as an emollient and moisturizer. Its in vivo effects are limited to topical applications. No systemic pharmacological effects are expected. It is used as a cosmetic ingredient and is not administered systemically.
|
| ADME/Pharmacokinetics |
Cetyl glycol has a molecular weight of 258.44 g/mol (C16H34O2). It is a long-chain diol. It is insoluble in water and soluble in organic solvents. It is a waxy solid at room temperature. It is used as a cosmetic ingredient and chemical intermediate. Its pharmacokinetic properties are not relevant for its topical use.
|
| Toxicity/Toxicokinetics |
Cetyl glycol has a favorable safety profile for topical use. It is generally recognized as safe for use in cosmetic products. It may cause skin irritation in sensitive individuals. The compound should be used at recommended concentrations. It is not intended for ingestion or systemic administration.
|
| Additional Infomation |
1,2-Hexadecanediol is a diol formed by substituting hydroxyl groups at the 1 and 2 positions of hexadecane. It is derived from the hydride of hexadecane.
Cetyl glycol (CAS 6920-24-7) is a long-chain diol used as an emollient, emulsifier, and thickening agent in cosmetic and personal care products. It has moisturizing properties and is used in skin care formulations. It has no approved therapeutic indications and is not a pharmaceutical drug. It is used primarily as a cosmetic ingredient and chemical intermediate. |
| Molecular Formula |
C18H34O3
|
|---|---|
| Molecular Weight |
298.47
|
| Exact Mass |
258.255
|
| CAS # |
6920-24-7
|
| PubChem CID |
98037
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
361.9±0.0 °C at 760 mmHg
|
| Melting Point |
68-72ºC(lit.)
|
| Flash Point |
164.9±13.6 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.463
|
| LogP |
5.25
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
18
|
| Complexity |
148
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C([H])(C([H])([H])O[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
IMYZYCNQZDBZBQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H34O3/c1-2-3-4-5-7-10-13-16-17(21-16)14-11-8-6-9-12-15-18(19)20/h16-17H,2-15H2,1H3,(H,19,20)
|
| Chemical Name |
Cetyl glycol
|
| Synonyms |
Cetyl glycol NSC-71525 NSC71525NSC 71525
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3504 mL | 16.7521 mL | 33.5042 mL | |
| 5 mM | 0.6701 mL | 3.3504 mL | 6.7008 mL | |
| 10 mM | 0.3350 mL | 1.6752 mL | 3.3504 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05886673 | RECRUITING | Other: experimental cream Other: standard of care |
Radiodermatitis | Antonio J. Conde Moreno | 2023-03-29 | Not Applicable |
| NCT00924508 | TERMINATEDWITH RESULTS | Device: hydrogel patch Drug: Triamcinolone (TAC) 0.1% cream |
Eczema | University of California, San Francisco | 2008-07 | Not Applicable |
| NCT06122467 | COMPLETED | Other: EQ Exfoliating Cleanser Other: EQ Gel Other: EQ Moisturizer |
Acne | Menning Labs | 2023-10-02 | Not Applicable |
| NCT01898182 | COMPLETED | Other: Kinetin, N6-furfuryladenine, 0.1% | Cutaneous Photoaging | Makati Medical Center | 2013-11 | Phase 4 |
| NCT06125912 | COMPLETED | Other: Dime Beauty TBT Cream Other: Positive Control |
Skin Aging | Dime Beauty Co. | 2023-09-25 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
